Topic: non-small cell lung cancer
The FDA cleared Roche’s cobas EGFR test for use as a companion diagnostic for AstraZeneca’s Iressa in first-line non-small cell lung cancer.
After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.
The actions affect anti-IL7R antibody PF-06342674 and third-generation, mutant-selective EGFR tyrosine kinase inhibitor PF-06747775.
Vaccinex filed a $46 million Nasdaq IPO to support its development of antibodies and conjugates targeting neurodegenerative diseases and cancer.
The results of a phase 3 trial suggest dacomitinib is more effective than its aging rival.
The funding will advance Rain's hypoxia-activated prodrug in patients with non-small cell lung cancer for whom there are no treatments.
The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.
Syndax’s entinostat-Keytruda combination may have posted small gains in NSCLC, but an enrichment biomarker could predict increased clinical benefit.
The drug shrunk the tumors of most patients in the trial, raising hopes it can become a new treatment option for patients with RET-altered cancers.
Blueprint's data shows its BLU-667 caused some tumor shrinkage in 84% of patients with lung or thyroid cancer.